Cleveland, Ohio (PRWEB) September 19, 2012
Cleveland, Ohio, law firm Spangenberg Shibley & Liber is now investigating claims involving individuals who developed type 2 diabetes while taking cholesterol-lowering brand name drug Crestor, or rosuvastatin calcium.
The U.S. Food and Drug Administration approved Crestor in August 2003 to reduce the level of bad, or LDL, cholesterol in the blood stream. LDL accumulates in blood vessel walls, which puts a person at greater risk of developing a blood clot that may cause a heart attack, according to WebMD. When exercise, a heart-healthy diet, and weight loss don’t lower cholesterol levels, a doctor may prescribe a once-a-day statin pill to help. WebMD says that statins such as Crestor, Zocor and Lipitor block a liver enzyme that produces cholesterol.
In February 2010, The Lancet reported that out of 90,000 participants in previous clinical trials, statin users showed a nine percent higher risk of developing type 2 diabetes compared to those who did not take a statin.
In June 2011, a study published in the Journal of the American Medical Association reported that out of 32,752 participants in previous clinical trials, 2,749 developed type 2 diabetes while taking a high dose of statin medication. This equated to an elevated risk of 12 percent over those who’d taken a moderate dose.
Flash-forward to January 2012 and the Archives of Internal Medicine published a study of nearly 162,000 women between ages 50 and 79. This study found that those participants who’d taken statins “were 48 percent more likely to develop type 2 diabetes than women who did not.”
“Doctors aren’t sure why the medication is associated with higher rates of type 2 diabetes,” reported Time magazine writer Meredith Melnick. “But one possible explanation is that they increase blood sugar levels.” Likewise, a doctor who’s consulted for statin manufacturers told New York Times blogger Tara Parker-Pope that results of animal studies point to an increase in muscles’ resistance to insulin, which results in higher blood sugar levels.
This increase in blood sugar levels prompted the FDA to approve warning label changes for statin drugs.
“Based on clinical trial meta-analyses and epidemiological data from the published literature,” the FDA reported in February, “information concerning an effect of statins on incident diabetes and increases in HbA1c and/or fasting plasma glucose was added to statin labels.”
About Spangenberg Shibley & Liber
Spangenberg Shibley & Liber handles a broad range of dangerous drug, personal injury, medical malpractice, nursing home and elder abuse and civil rights cases. The firm also litigates a variety of property damage and insurance coverage cases. For more information about the firm, please contact marketing manager Miranda Miller at 216.696.3232 or visit spanglaw.com.